

# FUTURE ONCOLOGY

TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES

A NEW MEDICINE PUBLICATION

VOLUME 5, NUMBER 1-12 INDEX

SEPTEMBER 2000

## TABLE OF CONTENTS

<b>STATE-OF-THE-ART IN THE MANAGEMENT OF CANCER</b>			
<b>KIDNEY CANCER — PART IV IMMUNOTHERAPY/TUMOR VACCINES</b>			
<b>ADOPTIVE IMMUNOTHERAPY</b>	1022		
Lymphokine-activated Killer (LAK) Cells	1022		
Tumor-infiltrating Lymphocytes (TILs)	1022		
Tumor-Sensitized Lymph Node Cells	1023		
Autolymphocyte Therapy (ALT)	1023		
Dendritic Cells (DC)	1023		
<b>ACTIVE SPECIFIC IMMUNOTHERAPY</b>	1024		
Autologous Tumor Vaccines	1024		
Autologous Tumor-Derived Heat Shock Protein-Peptide Complex-96 (HSPPC) Vaccine	1024		
Tumor-Specific, Mutated, von Hippel-Lindau Peptides	1024		
CD40 Ligand (CD40L)	1025		
<b>LUNG CANCER — PART I ETIOLOGY AND GLOBAL EPIDEMIOLOGY</b>			
<b>GLOBAL EPIDEMIOLOGY</b>	1041		
<b>TRIAD EPIDEMIOLOGY</b>	1042		
Lung Cancer in the USA	1042		
Lung Cancer in Europe	1042		
Lung Cancer in Japan	1042		
<b>ETIOLOGY</b>	1043		
Tobacco Smoking	1043		
Environmental Factors	1045		
Hereditary Factors	1045		
<b>LUNG CANCER — PART II SCREENING, DIAGNOSIS, AND CLASSIFICATION</b>			
<b>LUNG CANCER SCREENING</b>	1074		
Chest X-ray	1076		
Low-dose Helical Computed Tomography (CT)	1076		
Sputum Cytology	1078		
Breath Analysis	1079		
Molecular Markers	1079		
<b>PRESENTATION AND DIAGNOSIS</b>	1080		
Brush Cytology	1080		
Endoscopy/Bronchoscopy	1080		
Biopsy	1083		
Noninvasive Imaging	1083		
<i>Computed tomography (CT)</i>	1083		
<i>Nuclear medicine</i>	1083		
<b>HISTOLOGY AND CLASSIFICATION</b>	1084		
<b>LUNG CANCER — PART III SMALL CELL LUNG CANCER-EPIDEMIOLOGY, TUMOR MARKERS, STAGING, PROGNOSIS, DISEASE MONITORING, AND CURRENT TREATMENT STRATEGIES</b>			
<b>EPIDEMIOLOGY</b>	1105		
<b>TUMOR MARKERS</b>	1106		
Oncogenes and Tumor Suppressor Genes	1106		
Neuroendocrine Markers	1106		
<b>DIAGNOSIS, STAGING, PROGNOSIS AND DISEASE MONITORING</b>	1106		
Serum Markers	1107		
<i>Neuron-specific enolase</i>	1108		
<i>Pro-gastrin-releasing peptide</i>	1108		
<i>Chromogranin A</i>	1108		
<i>Multiple serum markers</i>	1108		
Angiogenesis Markers	1109		
Detection of Tumor Cells in Bone Marrow	1111		
Noninvasive Imaging	1112		
<i>Bone Scans</i>	1112		
<i>Scintigraphy</i>	1112		
<i>Positron emission tomography (PET)</i>	1114		
<b>TREATMENT OF PRIMARY SCLC</b>	1114		
Surgery	1115		
Radiation Therapy (RT)	1116		
<i>Thoracic radiation therapy (RT)</i>	1116		
<i>Prophylactic cranial irradiation (PCI)</i>	1116		
Chemotherapy	1117		
<i>Combination chemotherapy</i>	1117		
<i>Single-agent chemotherapy</i>	1118		
<i>Intensive chemotherapy/chemoradiotherapy</i>	1124		
<b>MANAGEMENT OF REFRACTORY/RELAPSED SCLC</b>	1126		
Drug Resistance in SCLC	1126		
Second-line Chemotherapy	1127		
<i>Gemcitabine</i>	1127		
<i>Topotecan</i>	1127		
<i>Paclitaxel</i>	1127		
<b>LUNG CANCER — PART IV NON-SMALL-CELL LUNG CANCER-EPIDEMIOLOGY, TUMOR MARKERS, DIAGNOSIS, STAGING, AND PROGNOSIS</b>			
<b>EPIDEMIOLOGY</b>	1129		
Gender Variations in the Incidence of NSCLC	1129		
Age Factors in the Incidence of NSCLC	1131		
Stage at Diagnosis	1131		
Survival	1131		
NSCLC Incidence by Histologic Type	1131		
<b>TUMOR MARKERS</b>	1133		
Hereditary Factors	1133		
Other Biomarkers	1135		
<b>DIAGNOSIS AND SCREENING</b>	1135		
Noninvasive Imaging	1135		
<i>Electron beam tomography (EBT)</i>	1135		

Positron emission tomography (PET) 1135

*In vitro* Approaches 1135

Cell-associated transferrin receptor (TfR) 1135

Cyfra 21-1 1135

DR-70 1136

Gastrin-releasing protein receptor (GRPr) 1136

Heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 1136

Homeobox (HOX) genes 1141

MAb 28K29 1142

Micrometastases detection 1142

Microsatellite alterations 1142

Telomerase 1142

**STAGING** 1143

Revisions in the International System for Staging Lung Cancer 1143

Noninvasive Imaging 1143

CT staging 1143

FDG PET imaging 1143

MR scanning 1144

Surgical Staging 1144

Mediastinotomy/mediastinoscopy 1144

Thoracoscopy and video-assisted thoracoscopy (VATS) 1144

Intra-operative sentinel lymph node mapping 1144

Molecular Substaging 1145

**PROGNOSIS** 1146

Serum Markers 1146

Tissue Pathology 1147

Angiogenesis evaluation 1147

Genetic Tests 1147

FDG PET Imaging 1148

**LUNG CANCER — PART V**

**NON-SMALL-CELL LUNG CANCER-CURRENT MANAGEMENT STRATEGIES**

**EPIDEMIOLOGY BY AGE AND STAGE IN THE USA** 1150

Incidence of NSCLC by Gender and Age 1150

Incidence of NSCLC by Stage 1150

First-year and Five-year Survival by Stage 1150

Treatment Approaches by Stage 1150

**SURGERY** 1150

Curative Surgery 1150

Minimally invasive surgery 1151

Video-assisted thoracic surgery (VATS) 1152

Surgery in Lung Metastases 1152

**RADIOTHERAPY (RT)** 1153

External Beam Radiotherapy 1153

Intensity Modulated Radiation Therapy (IMRT) 1155

Brachytherapy 1155

Intraluminal brachytherapy 1155

Intraoperative brachytherapy 1155

Proton-beam Radiotherapy 1156

**CHEMOTHERAPY** 1156

Types of Chemotherapy in NSCLC 1164

Single-agent chemotherapy 1164

Combination chemotherapy 1164

High-dose chemotherapy 1166

Novel Chemotherapeutics Approved for the Treatment of NSCLC 1166

**BIOLOGIC AGENTS** 1166

Interleukin 2 (IL-2) 1166

Interferon  $\beta$  (IFN- $\beta$ ) 1166

**MULTIMODALITY THERAPY** 1167

Adjuvant Chemotherapy 1167

Chemoradiotherapy 1168

Neoadjuvant/Induction Chemotherapy and Trimodality Therapy 1168

**OTHER TREATMENT MODALITIES** 1181

Laser Ablation 1181

Photodynamic Therapy (PDT) 1181

Photofrin 1182

LumaCare LC-051 1183

PH-10 1183

Hyperthermia 1183

BSD-2000/3D System 1184

Perfusion-induced systemic hyperthermia (PISH) 1184

Cryotherapy 1184

Radiofrequency bronchoscopic surgery with cryotherapy 1184

Stents 1185

Silicone stents 1185

Expandable metallic stents 1185

**LUNG CANCER — PART VI**

**NOVEL AGENTS/FORMULATIONS IN DEVELOPMENT**

**NOVEL CHEMOTHERAPEUTICS** 1190

Spindle Poisons 1191

Anhydrovinblastine 1191

BMS-184476 1191

Maytansinoid immunoconjugates 1191

PG-TXL 1192

Taxoprexin 1192

T67 1192

Topoisomerase I Inhibitors 1192

Exatecan mesylate 1192

TAS-103 1192

XR5000 1193

Antifolates 1193

Alimta 1193

S-1 1193

Nucleosides 1193

Decitabine 1193

FMdC 1193

Platinum-based Agents 1202

Nedaplatin 1202

Oxaliplatin 1203

Satraplatin 1203

Other Agents 1203

Bendamustine 1203

CHS 828 1203

CI-994 1204

Irofulven 1204

Temozolomide 1204

Tirapazamine 1204

**NOVEL FORMULATIONS AND DRUG DELIVERY APPROACHES** 1205

Lipid Formulations 1205

Onco TCS 1205

Liposome-encapsulated paclitaxel 1205

Aerosol Delivery 1205

Aerosol doxorubicin 1206

Aerosol retinoids 1206

Aerosolized GM-CSF 1206

Inhaled RFS 2000 1206

**ANGIOGENESIS INHIBITORS** 1206

Matrix Metalloproteinase Inhibitors (MMPI) 1206

BMS-275291 1207

Marimastat 1207

Neovastat 1207

Prinomastat 1208

Angiostatin and Endostatin 1208

Squalamine 1208

VEGF Antagonists	1208	<i>Pantacea</i>	1219	<i>Telomerase</i>	1261
<i>Angiozyme</i>	1208	Radiosensitizers	1219	<i>p53 mutations and other genetic markers</i>	1262
<i>rhuMab-VEGF</i>	1209	<i>KIN-806</i>	1219	<i>Cytokeratin (CK)</i>	1264
<i>Semoxind</i>	1209	<i>Motexafin gadolinium</i>	1219	<i>Hyaluronic acid (HA) and hyaluronidase (HAase)</i>	1266
Other Agents	1209	<i>RSR-13</i>	1220	Cystoscopy/Biopsy	1266
<i>BN-50730</i>	1209	Proton Beam Therapy	1220	<b>HISTOPATHOLOGY AND BLADDER CANCER TYPES</b>	1267
<b>REGULATION</b>	1209	<b>CHEMOPREVENTION</b>	1221	Transitional Cell Carcinoma (TCC)	1267
Cell Cycle Regulation	1209	Vitamins	1221	Squamous Cell Carcinoma	1267
<i>Flavopiridol</i>	1209	Nonsteroidal Anti-inflammatory (NSAI) Drugs/Derivatives	1221	Adenocarcinoma	1267
<i>UCN-01</i>	1210	<i>Celecoxib</i>	1221	<b>STAGE AND GRADE</b>	1267
Approaches Targeting the Epidermal Growth Factor Receptor (EGFr)	1210	<i>Exisulind</i>	1221		
<i>ABX-EGF</i>	1210	Retinoids	1222		
<i>Trastuzumab</i>	1210	Thymalfasin	1223		
<i>ZD 1839</i>	1211				
Farnesyl Transferase Inhibitors (FTI)	1211	<b>BLADDER CANCER — PART I</b>			
<i>R11577</i>	1211	<b>ETIOLOGY, EPIDEMIOLOGY AND TUMOR MARKERS</b>			
<i>SCH 66336</i>	1211	<b>ETIOLOGY</b>	1225	<b>ANTICANCER DRUGS AND MARKETS</b>	
Approaches Targeting p53	1211	Tobacco Smoking	1225	<b>UPDATE ON TAXANES</b>	
<i>rAd/p53</i>	1211	Environmental and Occupational Exposure	1226	COMMERCIAL PRODUCTS	1025
<i>RPR/INGN 201</i>	1212	Lifestyle Factors	1227	Taxol	1025
<i>ONYX-015</i>	1212	Health Factors	1227	Taxotere	1026
Agents Targeting Other Markers	1212	<b>PATHOGENESIS</b>	1228	<b>CLINICAL INDICATIONS</b>	1026
<i>G3139</i>	1212	<b>EPIDEMIOLOGY</b>	1228	Ovarian Cancer	1026
<i>ISIS 3521</i>	1213	Global Incidence and Mortality	1228	Breast Cancer	1027
<b>IMMUNOTHERAPY/VACCINES</b>	1213	USA Incidence	1228	Lung Cancer	1028
Cytokine-producing Tumor Vaccines	1213	<i>Gender</i>	1228	Other Cancer Indications	1028
SRL172	1213	<i>Age</i>	1229	<b>THE OUTLOOK FOR TAXOL AND ITS COMPETITION</b>	1028
Vaccines Against CEA-expressing Tumors	1214	USA Prevalence	1229	Taxane Sources and Production Processes	1028
<i>Anti-CEA antibodies</i>	1214	<b>TUMOR MARKERS</b>	1229	<i>Aphios</i>	1029
<i>Recombinant viruses expressing CEA protein or peptides</i>	1214			<i>Cytoclonal Pharmaceuticals</i>	1029
<i>Dendritic cells expressing CEA</i>	1216	<b>BLADDER CANCER — PART II</b>		<i>Dabur India</i>	1029
Vaccines Against Ganglioside-expressing Tumors	1216	<b>SCREENING, DIAGNOSIS, STAGING AND FOLLOW-UP</b>		<i>NaPro BioTherapeutics</i>	1029
<i>Fucosyl-GM1-keyhole limpet hemocyanin (KLH) conjugate vaccine</i>	1217	<b>SCREENING</b>	1250	<i>Phytogen Life Sciences</i>	1029
<i>Mitomomab (BEC2)</i>	1217	<b>DIAGNOSIS AND FOLLOW-UP</b>	1253	<i>Phyton</i>	1030
Vaccines Against MUC-1-expressing Tumors	1217	<i>In Vitro</i> Testing Approaches	1253	<i>Samyang Genex</i>	1030
<i>BLP-25</i>	1217	<i>Urine cytology/cytopathology</i>	1255	<i>Xechem International</i>	1030
Vaccines Against Tumors Expressing HER2	1218	<i>ImmunoCyt</i>	1255	Generic Paclitaxel	1030
<i>HER2 Peptide Vaccine</i>	1218	<i>Quanticyt</i>	1255	<i>Faulding</i>	1030
<b>RADIATION THERAPY</b>	1219	<i>Bladder tumor antigen (BTA)</i>	1256	<i>IVAX/Immunex</i>	1031
Radioimmunoconjugates	1219	<i>Nuclear matrix proteins (NMP)</i>	1258	<i>Mylan Pharmaceuticals</i>	1032
		<i>NMP-22</i>	1258	<i>Sicor</i>	1032
		<i>BCLA-4</i>	1260	<i>SuperGen</i>	1032
		<i>Fibrin/fibrinogen degradation products (FDP)</i>	1261	<i>Yew Tree Pharmaceuticals</i>	1032
				Novel Formulations	1032
				<i>Abbott Laboratories</i>	1032
				<i>Baker Norton Pharmaceuticals/Teax</i>	1032

<i>Cell Therapeutics</i>	1033
<i>EnzyMed</i>	1033
<i>Guilford Pharmaceutical</i>	1033
<i>MacroMed</i>	1033
<i>Matrix Pharmaceutical</i>	1034
<i>NeoPharm</i>	1034
<i>PhytoGen Life Sciences</i>	1034
<i>Pharmacia &amp; Upjohn</i>	1034
<i>Protarga</i>	1034
<i>SuperGen</i>	1035
<i>STS Particles/Medisperse</i>	1035
<i>Xechem International</i>	1035
Novel Taxanes and Analogs	1036
<i>Aventis</i>	1036
<i>Bristol-Myers Squibb</i>	1036
<i>British Technology Group (BTG)</i>	1036
<i>Indena</i>	1036
<i>The Lipsome Company (TLC)</i>	1037
<i>Taxolog</i>	1037
<i>Xechem International</i>	1037
Next Generation of Tubulin Stabilizing Drugs/Spindle Poisons	1037
<i>Apramycin</i>	1037
<i>D-24851</i>	1037
<i>Discodermolide</i>	1038
<i>Eleutherobin</i>	1038
<i>Epothilones</i>	1038
<i>Halimide</i>	1038
<i>LY355703</i>	1038
<i>Laulimalide and isolaulimalide</i>	1039
<i>T138067</i>	1039

**TECHNOLOGY UPDATE**

**SYNTHETIC NUCLEIC ACID SEQUENCE-SPECIFIC CONSTRUCTS AS ONCOLOGY THERAPEUTICS — PART I**

MECHANISM OF ACTION	1229
DESIRABLE ATTRIBUTES OF SYNTHETIC NUCLEIC ACID SEQUENCES AS THERAPEUTICS	1230
Sequence Structure and Length	1230
Backbone Modifications and Consequences	1230
<i>Phosphorothioate (P=S) ODN</i>	1230
<i>Methylphosphonate (M=P) ODN</i>	1231
<i>N3'-P5' phosphoramidate (P=A) ODN</i>	1232

<i>Mixed-backbone ODN (MBO)</i>	1233
<i>Morpholino ODN</i>	1236
<i>Peptide nucleic acid (PNA) linkage ODN</i>	1236
<i>Locked nucleic acid (LNA) ODN</i>	1237
Delivery Strategies and Entry into Cells	1237
<i>Virus-mediated transfer</i>	1237
<i>Attachment of lipophilic groups</i>	1238
<i>Fusogenic peptides</i>	1238
<i>Phenoxazine-modified ODN</i>	1238
<i>Streptolysin O</i>	1239
<i>Electroporation</i>	1239
<i>Microinjection</i>	1239
<i>Scrape-loading</i>	1239
<i>Osmotic-loading or osmotic-lysis</i>	1239
<i>Syringe-medicated loading</i>	1239
<i>Hormone carriers</i>	1239
<i>Spherulites</i>	1240
<i>Cationic lipid facilitators (lipids and liposomes)</i>	1240

**SYNTHETIC NUCLEIC ACID SEQUENCE CONSTRUCTS AS ONCOLOGY THERAPEUTICS — PART II**

TYPES OF SYNTHETIC NUCLEIC ACID CONSTRUCTS IN DEVELOPMENT AS ONCOLOGY THERAPEUTICS	1269
<i>Antisense Oligos</i>	1269
<i>Triplex-Forming ODN (TFO)</i>	1269
<i>Catalytic Nucleic Acids/Ribozymes</i>	1270
<i>Hammerhead ribozymes</i>	1271
<i>Minizyme</i>	1271
<i>Maxizymes</i>	1271
<i>Hairpin ribozymes</i>	1271
<i>Snorbozymes</i>	1272
<i>Deoxyribozymes or DNA enzymes (DNAzymes)</i>	1272
<i>Dy-Tex ribozyme analogs</i>	1272
<i>Chimeric Nucleotides</i>	1272
<i>Intracellularly Produced Antisense RNA and DNA</i>	1273
<i>Aptamers</i>	1274
<i>Aptazymes</i>	1275
<i>Aptamers as diagnostics</i>	1276
BIOLOGICAL ACTIVITY OF ODN	1276
<i>CpG-containing ODN</i>	1276
<i>G-rich ODN</i>	1277

<i>ODN Conjugated to Radioisotopes</i>	1278
CLINICAL CONSIDERATIONS	1278
Toxicity	1278
Administration Route	1278
<i>Oral delivery</i>	1278
<i>Pulmonary delivery</i>	1279
Combination Therapy	1279
<i>Starburst polyamidoamine (PAMAM) dendrimers</i>	1241
<i>Copolymers</i>	1245
<i>Amphiphiles</i>	1245
<i>Porphyrins</i>	1246
<i>Carrier-ligand conjugates</i>	1246
<i>Controlled-released carriers</i>	1247
<i>Virosomes</i>	1247

**SPECIAL REVIEW**

**ONCOLOGY TRENDS PRODUCT MARKETS — PART I**

PLATINUM-BASED ANTICANCER AGENTS	1046
<i>Cisplatin</i>	1046
<i>Carboplatin</i>	1047
<i>Oxaliplatin</i>	1047
TOPOISOMERASE I INHIBITORS	1048
<i>Topotecan</i>	1049
<i>Irinotecan</i>	1050
THYMIDYLATE SYNTHASE INHIBITORS/ANTIFOLATES AND RELATED AGENTS	1050
<i>Capecitabine</i>	1051
<i>Raltitrexed</i>	1051
<i>UFT</i>	1051

**ONCOLOGY TRENDS PRODUCT MARKETS — PART II**

HORMONE MODULATING DRUGS	1084
<i>Antiestrogens</i>	1085
<i>Tamoxifene</i>	1085
<i>Raloxifene</i>	1085
<i>Toremifene</i>	1086
<i>Aromatase Inhibitors</i>	1086
<i>Anastrozole</i>	1087
<i>Exemestane</i>	1088
<i>Fadrozole</i>	1088
<i>Formestane</i>	1089
<i>Letrozole</i>	1089
<i>Antiandrogens</i>	1089
<i>Bicalutamide</i>	1090

<i>Cyproterone acetate</i>	1090	<i>Interferon α-2a</i>	1099	Neoadjuvant Chemoradiotherapy in Resectable Disease	1058	
<i>Flutamide</i>	1090	<i>Interferon α-2b</i>	1099	Induction Chemotherapy and Concomitant Chemoradiotherapy in Unresectable Stage III Disease	1059	
<i>Goserelin</i>	1090	Rituximab	1099	Concurrent Versus Sequential Chemoradiotherapy in Unresectable Disease	1060	
<i>Leuprolide acetate</i>	1091	Trastuzumab	1101	Postoperative Chemotherapy with or without Radiotherapy in Resected Disease	1060	
<i>Nilutamide</i>	1091	<b>ADJUNCT THERAPIES</b>	1101	<b>COMMERCIALLY AVAILABLE CHEMOTHERAPEUTICS IN CLINICAL TRIALS IN ADVANCED DISEASE</b>	1061	
<b>OTHER CHEMOTHERAPEUTICS</b>	1091	Amifostine	1101	Two-drug Combination/ Multimodality Therapies	1061	
Alitretinoin	1091	Colony Stimulating Factors	1102	<i>Platinum-based chemotherapy regimens</i>	1061	
Anthracyclines	1092	<i>Filgrastim</i>	1102	<i>Taxane-based combinations</i>	1066	
<i>Daunorubicin</i>	1092	<i>Lenograstim</i>	1102	<i>Other combinations</i>	1066	
<i>Epirubicin</i>	1092	<i>Sargramostim</i>	1102	Monochemotherapies	1067	
<i>Liposomal daunorubicin</i>	1092	Ocreotide Acetate	1103	<i>Docetaxel</i>	1067	
<i>Liposomal doxorubicin</i>	1092	Oprelvekin	1103	<i>Paclitaxel</i>	1069	
<i>Mitoxantrone</i>	1094	Pamidronate Disodium	1104	<i>Vinorelbine</i>	1070	
<i>Valrubicin</i>	1094			<i>Irinotecan</i>	1070	
Busulfan	1094	<b>MEETING COVERAGE</b>			Multidrug Regimens in Advanced Disease	1070
Carmustine Wafer	1094	<b>CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE 35TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, ATLANTA, GA; MAY 15-18, 1999</b>			<i>Three-drug platinum- containing regimens</i>	1070
Etoposide Phosphate	1095	<b>APPROACHES TO MAXIMIZE THE ROLE OF CHEMOTHERAPY IN NSCLC</b>			<i>A dose-intensive 4-drug combination</i>	1071
Flutarabine	1095					
Gemcitabine	1095					
Liposomal Cytarabine	1095					
Methoxsalen	1096					
Porfimer Sodium	1096					
Temozolomide	1096					
<b>BIOLOGICALS</b>	1098					
Aldesleukin	1098					
Denileukin Diftitox	1098					
Interferon α	1099					

**LIST OF EXHIBITS**

TITLE	PAGE	TITLE	PAGE	TITLE	PAGE
Historic and Forecast Taxane Sales in the USA and Abroad	XXXX	Global Sales of Selected Anticancer Drugs and Related Products	1054	Antiestrogen Drugs in Development	1097
Estimated Cases under Treatment with Taxol and Taxotere Worldwide (1997-1999)	XXXX	Select Platinum-based Drugs in Development	1057	Adverse Cardiac Events with Herceptin	1102
Competitive Strategies in the Paclitaxel Market	XXXX	Selected Topoisomerase I (Topo I) Inhibitors in Development	1062	Incidence and 5-year Survival Estimates of Patients with Small-Cell Lung Cancer in the USA	1107
Estimated Incidence of Lung Cancer Around the World by Gender in 1999	1043	Selected Thymidylate Synthase Inhibitors and Related Agents in Development	1068	Estimated Incidence of Small-Cell Lung Cancer in the Triad in 1999	1109
Estimated Mortality of Lung Cancer Around the World by Gender in 1999	1044	Estimated Number of Smokers over 18 Years-of-Age in the USA in 1999 by Gender and Age	1076	Selected Tumor Markers Associated with Small-Cell Lung Cancer	1110
Lung Cancer Incidence in Europe by Country and Gender in 1999	1047	Estimated Number of Smokers by Average Cigarettes Smoked per Day in the USA in 1999 by Gender and Age	1079	Standard treatment Options for Small-Cell Lung Cancer	1115
Lung Cancer Deaths by Gender in Europe by Country in 1999	1048	Projects Funded by the NCI Early Detection Research Network	1081	Estimated Small-Cell Lung Cancer Cases by Type of Treatment in the USA in 1999	1117
Lung Cancer Incidence and Deaths in the Triad in 1999	1053	Epidemiology of Lung Cancer in the USA by Type in 1999	1087	Combination and Multimodality Clinical Trials in Small-cell Lung Cancer	1119
				Histologic Classification of NSCLC and Estimated Incidence in the USA in 2000	1132

TITLE	PAGE	TITLE	PAGE	TITLE	PAGE
Staging of NSCLC	1134	Potential Numbers of Chemotherapy Regimens for the Treatment of Lung Cancer	1192	Estimated Mortality of Bladder Cancer by Age Group in the USA in 2000	1238
Biomarkers Associated with NSCLC	1137	Selected Agents in Development for the Treatment of Lung Cancer	1194	Markers Associated with Bladder Cancer	1242
Estimated Incidence of NSCLC by Gender and Age	1151	Estimated Incidence of Bladder Cancer Around the World by Region and Gender in 2000	1231	<i>In Vitro</i> Tests for the Screening, Diagnosis, and Monitoring of Bladder Cancer	1251
Estimated Stage Distribution at Diagnosis and 1-year and 5-year Survival of NSCLC Patients by Stage in the USA in 2000	1153	Estimated Mortality of Bladder Cancer Around the World by Region and Gender in 2000	1232	Comparison of BTA Stat and Cytology in Bladder Cancer Monitoring	1258
First-line Treatment of NSCLC by Stage in 2000	1154	Estimated Bladder Cancer Incidence in Europe by Country and Gender in 2000	1234	Comparisons of UBC, BTA and NMP-22 Tests	1268
Treatment Options and Prognosis by Stage	1157	Estimated Bladder Cancer Mortality in Europe by Country and Gender in 2000	1235	Incidence of Bladder Cancer by Histologic Type in the USA in 2000	1271
Novel Chemotherapeutics Approved in the USA for the Treatment of NSCLC	1159	Estimated Incidence of Bladder Cancer by Age Group in the USA in 2000	1236	Basis for Staging of Bladder Cancer	1273
Phase II and III Combination and Multimodality Clinical Trials in NSCLC	1169			Incidence of Bladder Cancer by Stage in the USA in 2000	1275
				Incidence of Bladder Cancer by Grade in the USA in 2000	1277

## INDEX OF COMPANIES & INSTITUTIONS

12 de Octubre Hospital	1123	Ambion	1252	Auckland Cancer Research Laboratory	1063, 1193, 1202	Berlex Laboratories	1054, 1095
Abbott Laboratories	1029, 1032, 1080, 1089, 1091, 1194, 1199, 1200, 1201	AMDL	1136	Auckland Hospital	1123	Bethany Medical Center	1165
Abgenix	1194, 1210	American Home Products (AHP)	1031, 1055, 1097, 1194	AVAX Technologies	1062	Betticher Institute of Medical Oncology	1123
Academisch Ziekenhuis der Vrije Universiteit	1119	American Pharmaceutical Partners (APP)	1046	Aventis	1025, 1026, 1036, 1037, 1049, 1118, 1054, 1055, 1160, 1091, 1095, 1102, 1194, 1197, 1198, 1209, 1222	BICO	1184
Access Pharmaceuticals	1057	Amgen	1055, 1089, 1090, 1102, 1120	Aventis Pasteur	1201, 1215	BioChem Pharma	1195
AccuMed International	1078, 1079	Amgen-Kirin	1055, 1102	AVI BioPharma	1236	BioControl Technology	1184
Addenbrookes NHS Trust	1264	Amrad	1102	Axcan Pharma	1162	BioInvent International	1194
ADL (Germany)	1259	AnorMED	1057, 1194	Azienda Ospedaliera San Luigi Gonzaga	1184	Biomeasure	1062
Advanced Bioscience Lab	1081	Amos Cancer Center	1120	Baker Norton Pharmaceuticals	1031, 1032	Biomira	1195, 1217
Aeterna Laboratories	1194, 1207	Ansan	1201	Banyu	1062	Biomoda	1251
Agouron Pharmaceuticals	1068, 1069, 1194, 1208	Anthra Pharmaceuticals	1094	Bard Diagnostic Sciences	1257	Bion Diagnostic Sciences	1252, 1257
Akademiska Hospital	1146	Antigenics	1024	Barnes-Jewish Hospital	1083	BioNumerik Pharmaceuticals	1062, 1068, 1195
Akorn	1183	Antisoma	1194	Bar-Ilan Research and Development	1201	BioStratum	1195
Albert Einstein Cancer Center	1166, 1215	Aphios	1029	Barr Laboratories	1054, 1083, 1085	biosyn	1167
Albert Einstein College of Medicine	1272	Aquila Biopharmaceuticals	1200, 1217	Battelle Pulmonary Therapeutics	1194, 1206	Bio-Technology General	1029
Alcoa	1253	Arcturus Engineering	1082	Bayer	1081, 1096, 1206, 1252	Boehringer Ingelheim	1031, 1200
Alkermes	1247	Armand-Frappier Institute	1245	Bayer Diagnostics	1141	Boehringer Mannheim	1055, 1057, 1109
Allegheny General Hospital	1052, 1156	Aronex Pharmaceuticals	1057, 1194	Baylor College of Medicine	1206, 1253, 1274	Boston Medical Center	1259
Allegheny University	1034	Arthur G. James Cancer Hospital & Richard J. Solove Research Institute	1206, 1220	Beaufour Ipsen	1194, 1209	Boston Scientific	1185
Allos Therapeutics	1194, 1220	Asahi Chemical Industry	1142	Beckman Coulter	1197, 1219	Brandford University	1097
Almirall Prodesfarma	1094	Asta Medica	1037, 1046, 1118, 1200, 1211	Bedford Laboratories	1046, 1092	Brigham and Women's Hospital	1145, 1181, 1247
AltaRex	1194	AstraZeneca	1051, 1054, 1055, 1057, 1068, 1085, 1087, 1088, 1090, 1097, 1193, 1194	Beijing Tumor Institute	1259	Bristol-Myers Squibb (BMS)	1025, 1026, 1027, 1028, 1029, 1030, 1032, 1036, 1037, 1038, 1046, 1047, 1051, 1054, 1057, 1093, 1095, 1101, 1117, 1118, 1122, 1161, 1163, 1191, 1192, 1193, 1195, 1196, 1200, 1201, 1203, 1207
Alza	1032, 1054, 1055, 1057, 1089, 1092, 1101, 1123, 1159, 1241	Atairgin Technologies	1081	Beki Diagnostics	1109, 1252		

British Biotech	1195, 1197, 1207	Clatterbridge Centre for Oncology	1124	DuPont Pharmaceuticals	1097, 1113, 1114	Galena	1031
British Columbia Cancer Agency	1162, 1241	Clayton Foundation for Research	1201	Duramed Pharmaceuticals	1097	GE Medical Systems	1077
British Technology Group (BTG)	1036, 1062	Cleveland Clinic Foundation	1186, 1208, 1254, 1259	Eastern Cooperative Oncology Group (ECOG)	1162, 1211, 1212	GelTex Pharmaceuticals	1197
Brooke Army Medical Center	1033	ClinSites	1033	Eastern Virginia Medical School	1082, 1250	Gem Pharmaceuticals	1199
Bryan	1185	COBE BCT	1081	Eichrom Technologies	1242, 1252, 1261	Genelabs Biotechnology	1197
Bryn Mawr College	1200	Codon Pharmaceuticals	1270	Eli Lilly	1038, 1047, 1048, 1054, 1068, 1085, 1086, 1095, 1097, 1159, 1161, 1193, 1196, 1201, 1222	Genentech	1026, 1027, 1054, 1099, 1101, 1197, 1209, 1210
BSD Medical	1184	Columbia University	1246	Ellis Fischel Cancer Center	1132	General Biologicals	1259
Burnham Institute	1197	Community Hospital of Hamburg	1122	Endorecherche	1097	General Hospital of Bolzano (Italy)	1266
Cancer Diagnostics	1142	Consultants in Blood Disorders and Cancer	1172	EntreMed	1196, 1208	GeneSense Technologies	1197
Cancer Research Campaign	1033, 1057, 1192, 1193, 1194, 1198, 1202, 1204, 1252, 1264	Cook	1185	Enzon	1099, 1196	Genetica	1081
Cancer Research Center of Hawaii	1039	Cordis	1185	EnzyMed	1033	Genetics Institute	1102
Cancer Therapeutics	1022	Corixa	1082, 1196, 1218	EORTC	1267	Genetix Pharmaceuticals	1197
Cangene	1101	C. R. Bard	1257	EpiGenesis	1279	Genetronics Biomedical	1239
Canji	1195, 1211	Cornell University	1030, 1172, 1217	Esteve	1200	Gensia Sicor	1032
Catholic University	1058	Coulter Pharmaceutical	1100	Europe Organization for the Research and Treatment of Cancer (EORTC)	1161, 1163, 1171, 1203, 1204, 1206, 1207, 1217	Genta	1236, 1197, 1212
Cedars-Sinai Medical Center	1180	Cross Cancer Center	1136, 1218	Exiqon	1237	Genzyme Molecular Oncology	1140, 1195
Cell Genesys	1195, 1196	Cyclex	1035, 1057, 1201	Faulding	1029, 1030, 1255	G. Gaslini Children's Hospital	1241
Cell Pathways	1195, 1221, 1222	CytImmune Sciences	1196	Feist-Weiller Cancer Center	1263	Georg-August-University	1113
Cell Therapeutics (CTI)	1033, 1062, 1192, 1195, 1196	Cytoclonal Pharmaceutics (CPI)	1029, 1196	Ferrer Internacional	1098, 1099	Georgetown University	1034, 1199, 1216
Cellcor	1023	Cytogen	1023	Ferring	1030	Geron	1252, 1261
Celltech Group	1207	CytoGenix	1274	Finnish Institute of Occupational Health	1130	Gesellschaft für Biotechnologische Forschung	1038
Centers for Disease Control and Prevention (CDC)	1042	Cytoskeleton	1037	Fisher Diagnostics	1259	Gilead Sciences	1062, 1092, 1238, 1274, 1275
Centre de Recherches de Biochimie Macromoléculaire	1245	Cytc	1079	Fisher Scientific	1259	Glaxo Wellcome	1054, 1055, 1062, 1068, 1275
Centre Hospitalier Intercommunal	1203	Cytovia	1195	Fletcher International	1195	Glaxo SmithKline	1163, 1196, 1197, 1198, 1218
Centre of Molecular Immunology (CIM)	1202	Dabur India	1029	Food and Drug Administration (FDA)	1255, 1256, 1258, 1259	Glycosyn Pharmaceuticals	1062
Centre Pluridisciplinaire d'Oncologie	1123	Daiichi Pharmaceutical	1062, 1192, 1196	Florida State University (FSU)	1037	Goodwin Biotechnology	1201
Centocor	1054	Daikin Industries	1196, 1219	Fordham University	1024	Gothenburg University	1059, 1170
Chiba University	1178	Dainippon Pharmaceutical	1199	Foundation for Blood Research	1133	Grant Laser Center	1182
Children's Hospital, Boston	1196, 1197	Dako	1255	Fox Chase Cancer Center	1205, 1209, 1215	Graves Gilbert Clinic	1172
ChiRex	1029	Dana-Farber Cancer Institute	1069, 1195, 1196, 1210	Fred Hutchinson Cancer Research Center	1218	Greenlane Hospital	1123
Chiron	1054, 1095, 1098, 1166, 1196, 1200	Dartmouth Medical	1198	Free University Hospital (The Netherlands)	1162	Gregorio Marañón Hospital	1123
ChromaVision Medical Systems	1251	David Bull Labs	1030	Frei-Universität Berlin	1247	Grelan Pharmaceutical	1195
Chugai Pharmaceutical	1046, 1055, 1095, 1098	David Grant Medical Center	1120	Freie Universität Berlin (Germany)	1256, 1266	Guilford Pharmaceuticals	1033, 1054, 1094, 1095
Ci-Tec	1183	Davis Cancer Center	1120	Fujirebio	1136, 1251	Hadassah Medical Center (Israel)	1257
CIBA Vision	1229	Dendritech	1244	Fujisawa	1046, 1196	Harbor Branch Oceanographic Institution (HBOI)	1038
Ciphergen Biosystems	1082, 1250, 1252	DepoTech	1095, 1096	Galderma Research & Development	1196, 1198	Harefield Hospital	1184
Circon	1081	DiagnoCure	1251, 1253, 1255			Harvard School of Public Health	1130
City of Hope National Medical Center	1272	Diatide	1112			Harvard University Medical School	1196, 1197, 1247

HemoCleanse	1184	Incyte Genomics	1198	Karolinska Institute	1237	Massachusetts Institute of Technology	1033, 1181, 1246, 1252, 1259
Herbert Irving Comprehensive Cancer Center	1166	Indena	1036	Kay Kendall Leukaemia Fund	1198	Matritech	1243, 1252, 1258, 1259
Hoag Cancer Center	1024, 1157	Indiana University	1089, 1173, 1174	Kellogg Cancer Center	1144	Matrix Pharmaceutical	1034, 1057, 1062, 1193, 1198
Hoechst Celanese	1199	Inex Pharmaceuticals	1062, 1198	Kent Cancer Centre	1214	Maxia Pharmaceuticals	1198
Hoffmann-La Roche	1050, 1054, 1055, 1057, 1069, 1089, 1099, 1101, 1102, 1194, 1197	InNova	1029	Kimeragen	1273	Maxim Pharmaceuticals	1195
Hood Laboratories	1185	Innovir Laboratories	1241	Kinki University School of Medicine	1171	Mayo Clinic	1045, 1074, 1102, 1157, 1160, 1183, 1206, 1209, 1211
Hôpital Arnaud de Villeneuve	1119	Inselspital	1171	Klinge Pharma	1097, 1102, 1200, 1203	Mayo Graduate School of Medicine	1254
Hôpital Ste-Marguerite	1121	INSERM	1130, 1240	Klinge Pharmaceuticals	1097	MBG Technologies	1183
Hospital Arnaud de Vilanova	1179	Institut de Genetique Moleculaire de Montpellier	1238	Klinikum Grosshadern (Germany)	1135, 1184	M. D. Anderson Cancer Center (MDACC)	1024, 1033, 1035, 1057, 1062, 1137, 1139, 1082, 1194, 1195, 1198, 1202, 1206, 1207, 1208, 1209, 1211, 1212, 1240, 1250, 1259
Hospital de Cruces	1173	Institut Curie	1036	Kliniken Ibbenbüren	1120	MDS Research Foundation	1037
Hospital del Mar	1180	Institut Henri Beaufour	1062	Konica	1259	Medarex	1199
Hospital Duran i Reynals	1113, 1114, 1173	Institute for Drug Development, Cancer Therapy and Research Center	1036	Kosan Biosciences	1038	Medeva	1094
Hospital Großhansdorf	1122	Institute of Biostructure	1183	KS Biomedix	1214	Medical Research Council (MRC)	1168
Hospital Gauting	1122	Institute of Cancer Research	1198	Kurume University School of Medicine	1178	MedImmune Oncology	1159
Hospital General Universitario de Alicante (Spain)	1265	Institute of Pathology, Berlin	1135	Kyomed	1097	Medisperse	1035
Hospital Vall d'Hebron	1101	International Agency for Research on Cancer	1130, 1227	Kyowa Hakko Kogyo	1068, 1198, 1200, 1210	Memorial-Sloan Kettering Cancer Center	1074, 1172, 1176, 1197, 1199, 1200, 1206, 1217
Hubei Medical University	1136	Intracel	1252	Lachema	1030	Menssana Research	1079
Humboldt-Universität zu Berlin	1271	Introgen Therapeutics	1198, 1212	Lemery	1032	Mentor	1252, 1261
Hybridon	1233	ISIS Innovation	1057	Leo Pharmaceutical Products	1198, 1203	Merck	1062, 1097, 1221
Hybritech	1259	Isis Pharmaceuticals	1198, 1213, 1233, 1236, 1246	Leukaemia Research Fund	1198	Merck KGaA	1197, 1199, 1217, 1256
Hydro Med Sciences	1089	Istituto Nazionale per la Ricerca sul Cancro	1213	Lexigen Pharmaceuticals	1198	Metaxas Memorial Cancer Hospital	1159, 1180
Hygeia Hospital	1174	Istituto Nazionale per lo Studio e la Cura dei Tumori	1164	Lexon	1142, 1252	MGI Pharma	1055, 1199, 1204
Hyseq	1138, 1197	Istituto Nazionale Tumori	1142, 1179	Ligand Pharmaceuticals	1091, 1092, 1097, 1098	Michigan Molecular Institute	1244
IBC Pharmaceuticals	1197, 1219	Ivax	1029, 1031, 1032	The Liposome Company	1037, 1055, 1093	Microvasive	1185
ICN Pharmaceuticals	1099	Janssen	1088	Lithuanian Oncology Center	1167	Middlesex Hospital-Meyerstein Institute	1119
IDEC Pharmaceuticals	1049, 1054, 1099, 1100	Janssen Biotech	1035, 1057, 1201	Loma Linda University Medical Center	1156, 1220	Miravant Medical Technologies	1182
IDL Biotech	1146, 1251, 1265	Janssen Pharmaceutica	1198	Lombardi Cancer Center	1081	Moffitt Cancer Center	1141
IDT	1184	Japan Tobacco	1194, 1195	Louisiana Oncology Associates	1172	Montana State University	1029
IGT Pharma	1191, 1197	Johann Wolfgang Goethe Universität	1245	Louisiana State University Health Sciences Center	1263	Mount Sinai Comprehensive Cancer Center	1176
Ilex Oncology	1063, 1068, 1196, 1197, 1207	Johns Hopkins University	1033, 1034, 1074, 1081, 1192, 1195, 1197	Lucca Hospital	1173	Mount Sinai School of Medicine	1024, 1082
Imatron	1135	Johnson & Johnson	1054, 1055, 1185, 1211	Ludwig-Maximilians University	1135	MPI Research	1068
ImClone Systems	1197, 1217	Johnson & Johnson Research	1239	LumaCare	1183	Munich University Medical School	1184
Immune Response	1246	Johnson Matthey	1057, 1203	Lungenklinik	1155	Mylan Pharmaceutical	1029, 1032, 1085
Immunex	1025, 1031, 1032, 1054, 1055, 1094, 1103, 1194, 1201, 1210	Jonsson Comprehensive Cancer Center	1210	Lynx Therapeutics	1233		
Immuno-Designed Molecules (IDM)	1199	Josai University	1269	MacroMed	1030, 1033		
ImmunoGen	1191, 1197, 1198	Kagoshima University	1069	Mallinckrodt	1112		
Immunomedics	1197, 1219	Kaiser Permanente	1209, 1228	Magainin Pharmaceuticals	1198, 1208		
Immunotech	1219	Kaplan Cancer Center	1211	Marie Lannelongue Hospital	1151		
Imperial Cancer Research Fund (ICRF)	1062, 1194, 1195, 1199, 1201	Karmanos Cancer Institute	1141	Martek Biosciences	1200		
Imperial Cancer Research Technology (ICRT)	1199, 1201	Karo Bio	1097	Massachusetts General Hospital	1181, 1246, 1259, 1275		



Myriad Genetics	1199	Nexagen	1275	Paladin Labs	1094, 1195, 1257	Robert H. Lurie Comprehensive Cancer Center	1081, 1168
Nanodesign	1097	Nexell Therapeutics	1142, 1241	Palmerston North Hospital	1123	Robert Wood Johnson (RWJ) Medical School	1269
NaPro BioTherapeutics	1029, 1030, 1031, 1032	NeXstar Pharmaceuticals	1030, 1054, 1055, 1062, 1275	Panum Institute	1236	Roberts Pharmaceutical	1086, 1089
National Cancer Center Hospital East	1157, 1174	Nippon Kayaku	1197	Parke-Davis	1097, 1197, 1199, 1204	Roche Diagnostics	1108, 1109, 1136, 1250, 1251, 1252, 1264
National Cancer Center Hospital	1120	Nordic Drugs	1030	Peptech	1199	Rockefeller University	1275
National Cancer Center Hospital	1202	Northwest Biotherapeutics	1199	PerImmune	1261	Roswell Park Cancer Institute	1036, 1191
National Cancer Institute (NCI)	1022, 1024, 1025, 1035, 1038, 1042, 1045, 1059, 1063, 1068, 1076, 1077, 1078, 1079, 1080, 1082, 1086, 1100, 1101, 1114, 1121, 1123, 1130, 1141, 1152, 1183, 1184, 1194, 1196, 1197, 1198, 1199, 1200, 1201, 1203, 1204, 1205, 1206, 1207, 1211, 1212, 1215, 1216, 1220, 1228, 1270	Northwestern University	1081, 1168	Pfizer	1097, 1194, 1199, 1202, 1208	Rotterdam Cancer Institute	1222
National Cancer Institute (Italy)	1240	Norton Healthcare	1031	Pharmachemie	1032, 1046, 1085, 1201	Roy Castle International Centre for Lung Cancer Research (RCIC)	1136, 1142, 1198
National Cancer Institute of Canada	1125, 1207	Novalon Pharmaceutical	1097	Pharmacia	1191, 1198, 1199, 1205, 1221	Royal Brompton Hospital	1158
National Center for Health Statistics (NCHS)	1042	Norvartis	1032, 1054, 1055, 1087, 1088, 1089, 1103, 1112, 1198, 1229	Pharmacia & Upjohn	1034, 1049, 1054, 1062, 1088, 1092, 1118	Royal Marsden Hospital	1214
National Hospital (Republic of South Africa)	1177	Novartis Horsham Research Centre	1279	Pharmacyclics	1182, 1199, 1272	Rüsch	1185
National Human Genome Research Institute (NHGRI)	1263	Novartis Pharma KK	1103	PharmaGenix	1274	Rush-Presbyterian St. Luke's Medical Center	1174
National Institute for Occupational Safety and Health (NIOSH)	1227	Novo Nordisk	1097	PharmaMar	1063, 1199	Russian Academy of Medical Sciences	1135
National Institute of Dental and Craniofacial Research (NIDCR)	1112	Novocastra Laboratories	1263	Phillips Petroleum	1253	Rutgers University	1062
National Institutes of Health (NIH)	1022, 1076, 1142, 1263	Novogen	1097	Photogen Technologies	1183	Saiseikai Central Hospital	1152
National Kyushu Cancer Center	1171, 1178	Novopharm Biotech	1202	PhytoGen Life Science	1029, 1030, 1032, 1034	Sakai Chemical Industry	1200
National Naval Medical Center	1133	Nycomed Amersham	1032, 1054, 1112, 1113, 1199	Pierre Fabré Medicament	1094	Samyang Genex	1030, 1033
National Research Council	1197	Nycomed Pharma	1094	Pierre Fabre Oncologie	1063	San Antonio Cancer Institute	1191
National Shikoku Cancer Center Hospital	1169	Ohio State University	1220	Policlinico Hospital	1181	Sangtec Medical	1109, 1251
National Taiwan University Hospital	1181	Oncogene Research Products	1081	Polymedco	1252, 1257	Sankyo	1055
National University Hospital/Rigshospitalet (Denmark)	1179	Oncology St. Gallen	1123	Praecis Pharmaceuticals	1089	Sanofi-Synthelabo	1047, 1054, 1163, 1200, 1203, 1204
Nebraska Medical Center	1245	Oncometrics	1078	Princeton University	1201	Santa Creu i Sant Pau	1123
NeoPharm	1034, 1199, 1205	Oncor	1270	Professional Compounding Centers of America	1274	Sapporo City General Hospital	1180
NeoRx	1113	Onyvax	1200	Progen Industries	1200	Sarah Cannon Cancer Center	1172, 1177, 1192
Netherlands Cancer Institute	1033, 1034, 1124	Onyx Pharmaceuticals	1199, 1212	Progenics Pharmaceuticals	1200, 1217	Schering AG	1054, 1090, 1100, 1167, 1275
Neuromedica	1034	Optivus	1220	Prolifix	1097	Schering-Plough	1054, 1055, 1086, 1090, 1096, 1097, 1098, 1099, 1101, 1159, 1195, 1199, 1200, 1204, 1211
New York Hospital/Cornell Medical Center	1077	ORCA Biosciences	1082	Proligo	1237	SciClone Pharmaceuticals	1222
New York State University	1034	Orebro Medical Centre Hospital	1175	Protarga	1034, 1192, 1200	Scotia Pharmaceuticals	1182, 1200
New York University	1063	Organon Teknika	1023	QLT Phototherapeutics	1054, 1096, 1162	Scripps Institute of Oceanography	1038, 1198
Newcastle General Hospital	1036	Orion Pharma	1054, 1055, 1086	Rajavithi Hospital	1175	Scripps Research Institute	1038, 1198
		Orphan Medical	1094	Rakepoll Holding	1032	Seinajoki Central Hospital (Finland)	1257
		Ortho Biotech, Janssen-Cilag	1023, 1055	Regina Elena Cancer Institute	1173	Sequus Pharmaceuticals	1054, 1057, 1092
		Osaka Central Hospital	1170	Regina Elena Institute for Cancer Research	1239	Serono	1167, 1200
		Osaka University Medical School	1069	Research Corporation Technologies (RCT)	1046	Servier Group	1200
		OSI Pharmaceuticals	1199	Research Genetics	1081		
		Ospedale Bellaria-Maggiore	1182	Research Triangle Pharmaceuticals (RTP)	1035		
		Ospedale S. Andrea	1178	Rhône-Poulenc Rorer (Aventis)	1025, 1063, 1123		
		Ospedale San Giovanni	1036	Ribosepharm	1200, 1203		
		Ospedale Santa Maria delle Croci	1147	Ribozyme Pharmaceuticals (RPI)	1200, 1208, 1271		
		Otsuka Pharmaceutical	1063, 1068, 1069, 1199				
		Oxford Glycosciences	1082				
		Pacific BioTechnologies	1029				

Shionogi	1057, 1200, 1202	Tokushima Bunri University	1247	University of Copenhagen	1236, 1237	University Medical School of Pecs	1144
Sicor	1032, 1057	Transgene	1195, 1201	University of Delaware	1273	Uppsala University	1146
Sicor de Mexico	1032	Triangle Pharmaceuticals	1202	University of Florida	1123, 1197	UroCor	1252
Sidney Kimmel Cancer Center	1198	Truman VA Hospital	1132	University of Gatzemeier	1122	U.S. Bioscience	1046, 1055, 1101, 1121
Siemens Medical Systems	1184	Tularik	1039, 1192, 1201	University of Iowa	1033	Uath State University	1039
Signal Pharmaceuticals	1097	Ultrafine Chemicals	1097	University of Kentucky	1063, 1201	VA Northern CA Health Care System	1120, 1210
SkyPharma	1095, 1096	Unimed Pharmaceuticals	1035, 1055	University of London, School of Pharmacy	1057	Valentis	1202
SmithKline Beecham	1049, 1055, 1093, 1097, 1100, 1118, 1122, 1124, 1165	Unita Operativa di Oncologia Medica	1170	University of Louisville School of Medicine	1182	ValiGen	1273
Southern Arizona VA HealthCare System	1205	Unitech	1058	University of Mainz	1166	Vanderbilt Cancer Center	1052
Southern Research Institute	1196, 1199, 1200	Universita Cattolica del Sacro Cuore	1178	University of Maryland	1081, 1142, 1238	Vanderbilt University	1053, 1174, 1209, 1220
Southwest Oncology Group (SWOG)	1163	Universita degli Studi	1146, 1153	University of Massachusetts	1272, 1278	Veterans Affairs Hospital, Durham	1153, 1176
Sparta Pharmaceuticals	1035, 1069, 1098	Université de Montreal	1272	University of Medicine and Dentistry of New Jersey (UMDNJ)	1269	Veterans' General Hospital-Taipei	1177
Spectral Imaging	1081	University College London	1118, 1200	University of Miami School of Medicine	1266	ViaCirQ	1184
SR Pharma	1200	University Hospital, Groningen	1124, 1177	University of Michigan	1033, 1081, 1244, 1275	Vincent T. Lombardi Cancer Research Center	1215
SRI International	1063	University Hospital Nijmegen (The Netherlands)	1251	University of Milan	1147	Vion	1202
St. Luke's Medical Center	1023	University Medical Center Nijmegen (The Netherlands)	1255, 1256	University of Minnesota School of Medicine	1147	Virgen del Rocío Hospital	1123
Stanford University	1213	University Hospital, Rotterdam	1222	University of Missouri	1132	Virgen de la Victoria Hospital	1123
Stehlin Foundation for Cancer Research	1049, 1063, 1201	University Hospital, Yugoslavia	1169	University of Montreal	1193	Virginia Tech	1036
STS Particles	1035	University Hospitals, Münster and Greifswald	1120	University of North Carolina	1245, 1246	Virogenetics	1215
Sugen	1200, 1209	University of Alabama at Birmingham	1233, 1277	University of Ottawa	1207	Viventia Biotech	1202
Sumitomo	1201	University of Alberta	1241	University of Padua	1115	VivoRx	1037
Sun Hill Glucose	1030	University of Arizona Cancer Center	1205, 1208	University of Pennsylvania	1039, 1058, 1183	Vysis	1252, 1263
SUNY	1036	University of Arizona Cancer Center	1205, 1208	University of Pennsylvania Health System's Institute for Human Gene Therapy	1246	Wadley Institutes	1196
SuperGen	1032, 1035, 1049, 1057, 1063, 1069, 1098, 1193, 1201, 1206	University of Basel (Switzerland)	1263	University of Pittsburgh	1023, 1063, 1082, 1121, 1130, 1162, 1196, 1242, 1252, 1260	Walther Cancer Institute	1173
Supratek Pharma	1245	University of Bern	1247	University of South Florida	1081	Warner-Lambert	1068, 1069, 1097
Syren Pharmaceuticals	1057	University of Berne	1123	University of Texas	1033, 1035, 1194, 1195, 1196, 1198, 1199, 1202, 1240	Washington State University	1029
Taiho Pharmaceutical	1063, 1069, 1097, 1192, 1193, 1195, 1200, 1201	University of British Columbia	1197, 1241	University of Texas at Austin	1272	Wayne State University	1180
Takara Shuzo	1214, 1218	University of California	1194, 1199, 1200, 1202, 1264	University of Texas Medical Branch	1184	Weill Medical College	1217
Takeda Chemical Industries	1055, 1091, 1191, 1197, 1198	University of California Davis Cancer Center	1210	University of Texas Southwestern Medical Center	1082	West Virginia University	1238
Tampere University Hospital	1151, 1257	University of California San Diego Cancer Center	1197, 1198	University of Tsukuba	1271	Weston Park Hospital	1120
Tanabe Seiyaku	1195	University of California, Santa Barbara	1236	University of Vienna	1176, 1255	Whitehead Institute	1195
TAP Holdings	1055, 1091	University of California, Los Angeles (UCLA)	1113, 1209	University of Virginia Health Sciences Center	1268	William Beaumont Hospital	1146
Taxolog	1037	University of Cambridge	1264	University of Washington	1082, 1196, 1218	Xechem International	1030, 1035, 1037
Temple University Cancer Center	1205	University of Chicago Cancer Research Center	1165, 1192, 1203, 1212	University of Wisconsin Comprehensive Cancer Center	1162, 1208	Xenova Group	1063, 1193, 1202
Teva	1032	University of Cincinnati	1159	University of York	1097	Xillix Technologies	1080
Therakos	1096	University of Colorado	1081, 1200, 1209, 1270, 1275			Yale Cancer Center	1160
Therion Biologics	1201, 1215, 1216					Yale University	1081, 1133, 1202, 1264, 1270, 1275
Thomas Jefferson University	1082, 1272, 1273					Yew Tree Pharmaceuticals	1032
Tiefenau Hospital	1171					York Medical	1202
Titan Pharmaceuticals	1201					Zambon Group	1196

## NEW MEDICINE'S ONCOLOGY KNOWLEDGEBASE (nm|OK)

### IS NOW ON THE WORLD WIDE WEB

NEW MEDICINE's Oncology KnowledgeBASE (nm|OK) is an invaluable internet resource for anyone involved with drug development in the oncology field. NEW MEDICINE has designed a means to keep track of the incredible amount of information generated daily in this field, providing a rationally organized compendium of thousands of pieces of data that can be searched with ease. Information is presented across many variables, logically sequestered to reveal activities in a specific arena of interest. Use of nm|OK is an important resource in the performance of market research/technology assessment studies, in evaluating licensing/collaboration opportunities, in product positioning, and in helping executives place new information impacting their business in context, on a daily basis.

#### FOUR MODULES OF nm|OK MAY BE NOW ACCESSED ON THE INTERNET INCLUDING:

##### New and Marketed Drug Module

These modules currently provide detailed information on **2,204** drugs in development, marketed drugs, drug targets, or enabling technologies, for treating cancer and complications associated with this disease and its treatment, such as anemia, cachexia, edema, emesis, hypercalcemia, infection, mucositis, neutropenia, pain, thrombocytopenia, xerostomia, etc. The database can be searched by:

- therapeutic indication (malignancy, pain, emesis, infection, etc.)
- cancer indication (breast, prostate, colorectal, etc.)
- clinical indication (metastatic melanoma, hormone-refractory prostate cancer, limited-stage small-cell lung cancer, etc.)
- clinical status (IND, phase I/II/III/IV, NDA)
- geographical location where trials are taking place
- drug category (taxane, topoisomerase I inhibitor, hormone modulator, etc.)

- drug type (protein/peptide, natural product, etc.)
- technology (immunotherapeutic/vaccine, monoclonal antibody, photodynamic therapy, etc.)
- mechanism (apoptosis enhancer, antiangiogenic, cell cycle modulator, etc.)
- administration route (oral, IV, nasal, intraperitoneal, intralesional, etc.)
- delivery mode (liposomal, electroporation, pumps, implants, etc.)
- primary developer or affiliate for a complete pipeline

##### **Additionally, records incorporate:**

- patent information
- price and market size for marketed drugs
- orphan drug status by indication
- description of various enabling technologies that may be used to discover novel cytotoxic/cytostatic, or immunomodulating agents

##### Company Module

Also, nm|OK profiles **1016** companies/developers describing their cancer-related activities, and presenting oncology pipelines.

##### Marker Module

This module currently comprises **350** records delineating the role of molecular markers in various malignancies. Records may be searched by marker and/or cancer indication.

##### PLANNED ADDITIONS TO THE DATABASE

nm|OK is a work in progress. Currently, an Access™-based cancer epidemiology module is in development and will be available in mid 2001. Numerous other modules are also in development, including a database of combination trials.

**For more information, or a demo of nm|OK call NEW MEDICINE at 949-830-0448  
or visit our web site at [oncologyknowledgebase.com](http://oncologyknowledgebase.com).**

**ORDERING & INQUIRY INFORMATION****FUTURE ONCOLOGY:**

FUTURE ONCOLOGY (ISSN 1082-331X) is published as 12 issues (several double issues) per year, with a free annual index listing companies/institutions and subjects covered, and a binder.

- YES, I want to order a subscription to FUTURE ONCOLOGY.

**Subscription Information:**

- One-year subscription is \$840 U.S. and \$900 abroad; please specify period (from \_\_\_\_\_ to \_\_\_\_\_). Additional subscriptions sent in the same envelope are \$390 each.

**Back Issues:**

- Volumes V2, V3, V4, and V5 are \$2,400 (U.S.) and \$2,460 (outside the U.S.).
- Volumes V4 and V5 are \$1,400 (U.S.) and \$1,460 (outside the U.S.).

**Inquiry Information:**

- Please send me a sample issue of FUTURE ONCOLOGY
- Please send me the index of Volumes 1, 2, 3, 4 and 5

**Oncology Knowledgebase (nm|OK):**

- YES, I want to order a order nm|OK.

nm|OK is available by subscription only and access is provided via a password. The annual subscription rate is \$2,950 for the first "seat" and \$290.00 for each additional seat for up to 5 seats in the same physical location. Subscription rates for company-wide distribution are negotiable, based on physical location/IP designation and number, of users.

Please enter my subscription to nm|OK to start on  
(date) \_\_\_\_\_ at \$2,950.00 \_\_\_\_\_  
Additional seats # \_\_\_\_\_ at \$290.00 each \_\_\_\_\_  
Total \_\_\_\_\_

**Inquiry Information:**

- Please call me for a walk-through the database and a complimentary pass.

**Sale of NEW MEDICINE hard copy and electronic publications is made under the following conditions:**

Unauthorized photocopying, distribution or electronic storage is strictly prohibited. Information incorporated in NEW MEDICINE products is developed from various sources believed to be reliable. There can be no assurance that such information is accurate in all respects, however, and the publisher cannot be held liable for errors. Errors, when discovered, will be corrected. Subscriptions may not be canceled, but may be transferred.

All orders must be repaid or accompanied by a signed order form or P.O. #. Subscriptions to FUTURE ONCOLOGY and nm|OK will begin upon receipt of payment. Products are nonreturnable; please, feel free to call for information.

My check for \$ \_\_\_\_\_ is enclosed (make checks payable to NEW MEDICINE, INC.). Payment must accompany your order; checks must be drawn on a U.S. bank

**Wire Transfer:**

Washington Mutual, 400 East Main Street.  
Stockton, CA 95290. 800-374-4646. Routing #321180748.  
NEW MEDICINE INC. Account #087900008012618

**Credit Card:**  Visa  AmEx  M/C Exp. Date: \_\_\_\_\_

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Bill me on P.O. #: \_\_\_\_\_

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_ Company: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_

Zip Code: \_\_\_\_\_ Country: \_\_\_\_\_

Telephone: \_\_\_\_\_ Fax: \_\_\_\_\_

E-mail \_\_\_\_\_

**Return to: NEW MEDICINE, INC.:**

P.O. Box 909 • Lake Forest • CA 92630  
Telephone: (949) 830-0448 • Fax: (949) 830-0887  
E-mail: info@newmedinc.com  
Web Sites: www: newmedinc.com  
www.oncologyknowledgebase.com

**FUTURE ONCOLOGY Staff:**

PUBLISHER AND EDITOR:	<b>Katie Siafaca, MS</b>
ASSOCIATE EDITOR:	<b>Timothy Sharon, PhD</b>
ASSISTANT EDITOR:	<b>Adele Simon</b>
CIRCULATION:	<b>Amish Kalyani</b>
DESIGN & PRODUCTION:	<b>Jill Burch</b>

**EDITORIAL BOARD****BIOTECHNOLOGY & APPLIED SCIENCES:**

**James W. Hawkins, PhD**, Editor, Antisense Research and Development

**CLINICAL PRACTICE:**

**Leonard Sender, MD**, Medical Director, Hemtopoietic Stem Cell Program, St. Joseph Hospital Regional Center, Orange, CA

**REIMBURSEMENT AND MANAGED CARE:**

**Elan Rubinstein, PharmD, MPH**, Consultant